CHEN, ISAN,HAGER, JEFFREY H.,MANEVAL, EDNA CHOW,HERBERT, MARK R.,SMITH, NICHOLAS D.
申请号：
PE2015001343
公开号：
PE20151250A1
申请日:
2014.01.09
申请国别(地区):
PE
年份:
2015
代理人:
摘要：
The substance refers to a pharmacological compound of lipidica non-aqueous solution, including: (a) a formula compound (I) 4 - [7 - (6-cyano-5-trifluorpyridine-3-il) - 8-oxo-6-thio-5, 7-dioxane-5, 7-diazo [3.4] oct-5-il] - 2-fluoro-n-methylbenzene zamida； (b) a vitamin e-α-tocol-polyethylene-1000 perfluorooctane sulfonic acid (vitamin E)；(c) Polyethylene glycol 400 NF / EP (PEG 400)；(d) Glicerol monocapillo captato RP； and (E) caprilocapril macrographieros EP / NF. It also mentions a treatment for prostate cancer and diseases that can be treated with androgeno receptor modulators.SE REFIERE A UNA COMPOSICION FARMACEUTICA DE SOLUCION NO ACUOSA DE BASE LIPIDICA QUE COMPRENDE: A) UN COMPUESTO DE FORMULA (I) QUE ES 4-[7-(6-CIANO-5-TRIFLUOROMETILPIRIDIN-3-IL)-8-OXO-6-TIOXO-5,7-DIAZAESPIRO[3.4]OCT-5-IL]-2-FLUORO-N-METILBENZAMIDA； B) SUCCINATO DE VITAMINA E D-ALFA-TOCOFERIL POLIETILENGLICOL 1000 NF (VITAMINA E TPGS)； C) POLIETILENGLICOL 400 NF/EP (PEG 400)； D) GLICEROL MONOCAPRILOCAPRATO RP； Y E) CAPRILOCAPROIL MACROGLICERIDOS EP/NF. TAMBIEN SE REFIERE A UN METODO PARA EL TRATAMIENTO DE CANCER DE PROSTATA AVANZADO Y TRASTORNOS QUE SON SUSCEPTIBLES DE TRATAMIENTO CON EL MODULADOR DEL RECEPTOR DE ANDROGENO
